Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $14.4 million.

  • Anika Therapeutics' Accumulated Expenses fell 2317.53% to $14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.4 million, marking a year-over-year decrease of 2317.53%. This contributed to the annual value of $13.6 million for FY2024, which is 354.76% down from last year.
  • As of Q3 2025, Anika Therapeutics' Accumulated Expenses stood at $14.4 million, which was down 2317.53% from $11.3 million recorded in Q2 2025.
  • Anika Therapeutics' Accumulated Expenses' 5-year high stood at $19.8 million during Q3 2023, with a 5-year trough of $11.3 million in Q2 2025.
  • In the last 5 years, Anika Therapeutics' Accumulated Expenses had a median value of $16.4 million in 2021 and averaged $16.2 million.
  • In the last 5 years, Anika Therapeutics' Accumulated Expenses surged by 2961.99% in 2023 and then plummeted by 3153.27% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' Accumulated Expenses stood at $17.8 million in 2021, then grew by 5.56% to $18.8 million in 2022, then dropped by 25.34% to $14.1 million in 2023, then fell by 3.55% to $13.6 million in 2024, then grew by 5.82% to $14.4 million in 2025.
  • Its Accumulated Expenses stands at $14.4 million for Q3 2025, versus $11.3 million for Q2 2025 and $12.6 million for Q1 2025.